Doxazosin Tablet
Product Images NDC 50090-3927

4 FDA label images from A-s Medication Solutions · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Doxazosin (NDC 50090-3927). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Doxazosin Tablets, Usp (A308818e E36c 4431 Bf51 274650c38cb0 01)

Doxazosin Tablets, Usp (A308818e E36c 4431 Bf51 274650c38cb0 01)
Chemical structure of doxazosin, the active ingredient in the product. The diagram depicts the molecular composition including aromatic rings, nitrogen atoms, methoxy groups, and a methanesulfonic acid component.*
FDA Label Image

Doxazosin Tablets (A308818e E36c 4431 Bf51 274650c38cb0 02)

Doxazosin Tablets (A308818e E36c 4431 Bf51 274650c38cb0 02)
A data table summarizing results from three clinical studies comparing symptom score and maximum urinary flow rate between placebo and Doxazosin treatment groups. The table shows mean baseline and change values for symptom score and maximum flow rate across different dosages and study durations. The adjacent bar graph illustrates maximum flow rate changes in Study 2, showing dose-dependent increases for 4 mg and 8 mg Doxazosin compared to placebo.*
FDA Label Image

Doxazosin Tablets, Usp (A308818e E36c 4431 Bf51 274650c38cb0 03)

Doxazosin Tablets, Usp (A308818e E36c 4431 Bf51 274650c38cb0 03)
This figure contains two line graphs comparing the effects of Doxazosin versus placebo over a 14-week treatment period. The left graph depicts the mean change in total symptom score from baseline, showing a greater symptom reduction with Doxazosin (N=50) compared to placebo (N=47). The right graph shows mean increase in maximum urinary flow rate (mL/sec) from baseline, indicating higher flow rate improvements with Doxazosin versus placebo. Both graphs include error bars and denote statistical significance at various points.**
FDA Label Image

Label Image (Lbl500903927)

Label Image (Lbl500903927)
Doxazosin 4 mg oral tablets label from A-S Medication Solutions showing dosage strength as 4 mg, package size of 100 tablets, and storage instructions to store at 68 to 77 degrees Fahrenheit. The label includes NDC 50090-3927-1, lot number, and barcode information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.